Adjuvanted formulations of rabies virus immunogens
AssigneeNovartis AG
InventorsSiddhartha Jain, Derek O'Hagan, Manmohan Singh
Life of this patent
Estimating the term…
Abstract
The efficacy of rabies vaccines can be enhanced by adjuvanting rabies virus immunogens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. The rabies virus immunogen can also be adsorbed to the metal salt.
Claims32
An immunogenic composition comprising (i) an insoluble metal salt (ii) a human TLR agonist and (iii) a rabies virus immunogen.
An immunogenic composition comprising (i) an aluminium hydroxide adjuvant (ii) compound ‘K2’ or a pharmaceutically acceptable salt thereof, adsorbed to the aluminium hydroxide and (iii) an inactivated rabies virus, wherein compound K2 is according to the formula:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A process for preparing a sterile immunogenic composition, comprising steps of combining (i) a rabies virus immunogen with (ii) a sterile complex of a TLR agonist and an insoluble metal salt.
(canceled)
A composition comprising:
- (a) an adjuvant complex comprising a first TLR agonist adsorbed to an insoluble metal salt;
- (b) an adjuvant complex comprising a second TLR agonist adsorbed to an insoluble metal salt;
- and (c) a rabies virus immunogen.
Dependencies are inferred from the claim text.